Cargando…
Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease
BACKGROUND: Nesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabe...
Autores principales: | Ding, Shimei, Qu, Wei, Dang, Shuangsuo, Xie, Xuan, Xu, Jing, Wang, Yuhuan, Jing, Aiyu, Zhang, Chunhong, Wang, Junhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396685/ https://www.ncbi.nlm.nih.gov/pubmed/25841171 http://dx.doi.org/10.12659/MSM.892611 |
Ejemplares similares
-
Peripheral Effects of Nesfatin-1 on Glucose Homeostasis
por: Li, Ziru, et al.
Publicado: (2013) -
Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice
por: Mori, Yusaku, et al.
Publicado: (2019) -
Increased serum nesfatin-1 levels in patients with acromegaly
por: Yang, Yakun, et al.
Publicado: (2020) -
Serum levels of irisin and nesfatin-1 in multiple sclerosis
por: ALTAŞ, Mustafa, et al.
Publicado: (2022) -
Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus
por: Bonnet, Marion S, et al.
Publicado: (2009)